Abstract Background Carbapenem-resistant Acinetobacter baumannii infections are difficult
to treat and are a significant public health threat due to intrinsic/acquired resistance and …

Objectives To analyse the impact of cefiderocol use on outcome in patients admitted to the
ICU for severe COVID-19 and further diagnosed with carbapenem-resistant Acinetobacter …

Background. A large increase in multi-drug-resistant Acinetobacter baumannii, especially
carbapenem-resistant strains, occurred during the first two years of the COVID-19 pandemic …

Introduction Ventilator-associated pneumonia (VAP) caused by carbapenem-resistant
Acinetobacter baumannii (CRAB) in patients hospitalized in intensive care units (ICUs) is an …

Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to
carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center …

Introduction Acinetobacter baumannii is classified by the Center for Disease Control and
Prevention (CDC) as an" urgent threat" due to its ability to acquire and develop resistance to …

Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-
negative bacteria. We report our experience with cefiderocol-based combination therapies …

Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR)
Gramnegative bacteria. We report our experience with cefiderocol-based combination …

Background No clear evidence supports the use of cefiderocol as first line treatment in A.
baumannii infections. Methods We conducted an observational retrospective/prospective …

Appropriate antibiotic treatment for critically ill patients with serious Gram-negative infections
in the intensive care unit is crucial to minimize morbidity and mortality. Several new …